Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
Grey Wolf raises £10m for tumour ‘illumination’ techImmuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase Share XGrey Wolf raises £10m for tumour ‘illumination’ techhttps://pharmaphorum.com/news/grey-wolf-raises-10m-for-tumour-illumination-tech/
‘Trojan horse’ cancer drug shows promise in multiple tumour typesA new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has Share X‘Trojan horse’ cancer drug shows promise in multiple tumour typeshttps://pharmaphorum.com/news/trojan-horse-cancer-drug-shows-promise-multiple-tumour-types/
Daiichi gets speedy FDA review for rare cancer drugDaiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become Share XDaiichi gets speedy FDA review for rare cancer drughttps://pharmaphorum.com/news/daiichi-speedy-fda-review-rare-cancer-drug/
Sanofi’s Darzalex rival hits the mark in phase 3 trialJohnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition Share XSanofi’s Darzalex rival hits the mark in phase 3 trialhttps://pharmaphorum.com/news/sanofis-darzalex-rival-hits-the-mark-in-phase-3-trial/
GSK bolts-on immuno-oncology candidate with €3.7bn Merck dealGlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an Share XGSK bolts-on immuno-oncology candidate with €3.7bn Merck dealhttps://pharmaphorum.com/news/gsk-bolts-on-immuno-oncology-candidate-with-e3-7bn-merck-deal/
Roche seeks Kadcyla boost to fend off Herceptin biosimilarsAs biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer Share XRoche seeks Kadcyla boost to fend off Herceptin biosimilarshttps://pharmaphorum.com/news/roche-seeks-new-kadcyla-indication/
NICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomaNICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did Share XNICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomahttps://pharmaphorum.com/news/nice-approves-novartis-car-t-therapy-for-diffuse-large-b-cell-lymphoma/
Brexit could hinder CAR-T reimbursement in EuropeBrexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, Share XBrexit could hinder CAR-T reimbursement in Europehttps://pharmaphorum.com/news/brexit-could-hinder-car-t-reimbursement-in-europe/
Doctors and patient groups struggle with CAR-T ‘hype’Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are Share XDoctors and patient groups struggle with CAR-T ‘hype’https://pharmaphorum.com/news/doctors-and-patient-groups-struggle-with-car-t-hype/
CAR-T firms push to improve manufacturing efficiencyExperience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough Share XCAR-T firms push to improve manufacturing efficiencyhttps://pharmaphorum.com/news/car-t-firms-push-to-improve-manufacturing-efficiency/
Hope for CAR-T combination that could tackle solid tumoursGetting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a Share XHope for CAR-T combination that could tackle solid tumourshttps://pharmaphorum.com/news/hope-for-car-t-combination-that-could-tackle-solid-tumours/
No new patients should take Lilly’s cancer drug Lartruvo, say regulatorsRegulators on both sides of the Atlantic have ruled that no new patients should start treatment with Eli Share XNo new patients should take Lilly’s cancer drug Lartruvo, say regulatorshttps://pharmaphorum.com/news/no-new-patients-should-take-lillys-cancer-drug-lartruvo-say-regulators/
Documentaries lift lid on Theranos biotech scamAs criminal fraud investigations continue into former Theranos CEO Elizabeth Holmes and president Ramesh Balwani, further details are Share XDocumentaries lift lid on Theranos biotech scamhttps://pharmaphorum.com/news/documentaries-lift-lid-on-theranos-biotech-scam/
US patients receive Proteus’ digital chemotherapy pillCancer patients in the US are starting to use digital oncology drugs for the first time, collecting data Share XUS patients receive Proteus’ digital chemotherapy pillhttps://pharmaphorum.com/news/us-cancer-patients-trial-proteus-digital-chemotherapy-pill/
